Juraj Dúbrava
Temporary interruption of peroral anticoagulant therapy due to invasive diagnostic or therapeutic procedures can be
expected in approximately 25% of all patients within 2 years after its initiation. European Society of Cardiology and
European Heart Rhythm Association published the guidelines providing relatively easily applicable instructions how
to deal with anticoagulant therapy in a particular patient in a particular situation. Nevertheless, in routine practice we
meet with significant deviations from these recommendations. This article summarizes the most important information
regarding the management of anticoagulant therapy in patients treated with warfarin or novel peroral anticoagulants
undergoing invasive diagnostic or therapeutic procedures.